Is endothelial dysfunction induced by aromatase inhibitors reversible after treatment?
Breast Cancer Research and Treatment · 2026-06 · 217 (3)
DOI: 10.1007/s10549-026-08007-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, online erschienen am 22.06.2026. Verfasst von Mohamed S Dabour und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA. Hauptthemen laut MEDLINE: Aromatase Inhibitors, Endothelium, Vascular, Breast Neoplasms. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Aromatase inhibitors (AIs) are standard therapy for postmenopausal women with hormone receptor-positive breast cancer. However, prolonged AI use is associated with increased cardiovascular (CV) risk, including hypertension, and endothelial dysfunction. This study evaluated the longitudinal changes in endothelial function during AI therapy, and whether AI-induced endothelial dysfunction is reversible post-discontinuation.
Methods
Patients were recruited before or within one month of AI initiation (Pre/early AI), during AI therapy, and after discontinuation (Post-AI) from two prospective studies. Patients with hypertension, hyperlipidemia, diabetes, or tobacco use were excluded. Vascular assessments included peripheral arterial tonometry (EndoPAT) for endothelial function (abnormal if ratio < 1.67) and artery elasticity indices. Estradiol, lipid profiles, and inflammatory markers were also measured.
Results
The study included 12 Pre/early AI patients, 67 visits from 41 patients during AI (median 2.89 years on AI), and 9 Post-AI patients (median 4.17 years follow-up). EndoPAT ratio was significantly impaired during AI therapy compared to the Pre/early AI (median: 0.86 vs 2.19). The EndoPAT ratio declined as early as six months and showed a progressive decline over time. Post-discontinuation, the EndoPAT ratio was only partially and not significantly restored (median: 1.08) despite full estradiol restoration and long follow-up. Arterial elasticity showed no significant changes. Systolic blood pressure increased modestly during AI therapy and returned to baseline after discontinuation, while diastolic pressure remained unchanged. Circulating interleukin-6 and tumor necrosis factor-α significantly decreased following AI discontinuation.
Conclusions
AI therapy is associated with significant and progressive endothelial dysfunction, which does not fully recover after treatment cessation, highlighting the importance of CV monitoring in patients receiving long-term AI therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA.
- Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
- Division of Cardiology, AdventHealth Orlando, Orlando, FL, USA.
- Division of Cardiology, University of Minnesota, Minneapolis, MN, USA.
- Division of Hematology/Oncology/Transplantation, Medical School, University of Minnesota, 909 Fulton St SE, Minneapolis, MN, 55455, USA. blaes004@umn.edu.
ORCID-Profile: Anne H Blaes
Zitieren
APA
Dabour, M. S., Shaaban, A., Duprez, D. A., Zordoky, B. N., & Blaes, A. H. (2026). Is endothelial dysfunction induced by aromatase inhibitors reversible after treatment?. Breast Cancer Research and Treatment, 217(3). https://doi.org/10.1007/s10549-026-08007-2
Vancouver
Dabour MS, Shaaban A, Duprez DA, Zordoky BN, Blaes AH. Is endothelial dysfunction induced by aromatase inhibitors reversible after treatment?. Breast Cancer Research and Treatment. 2026;217(3). doi:10.1007/s10549-026-08007-2
BibTeX
@article{Dabour2026,
author = {Dabour, Mohamed S and Shaaban, Adnan and Duprez, Daniel A and Zordoky, Beshay N and Blaes, Anne H},
title = {Is endothelial dysfunction induced by aromatase inhibitors reversible after treatment?},
journal = {Breast Cancer Research and Treatment},
year = {2026},
volume = {217},
number = {3},
doi = {10.1007/s10549-026-08007-2}
}
EUVIMED